# BioMarin Pharmaceutical Inc. (BMRN)

> Source: Nexqual · https://nexqual.com/BMRN · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, BioMarin Pharmaceutical Inc. (BMRN), nexqual.com/BMRN" · informational, not investment advice.

**Price:** USD 56.63 (+2.57% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 55.21 · day 55.02–56.91 · 52w 49.26–70.98 · market cap $11.0B · NMS

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $3.41B, net income $73.0M (2.1% margin), free cash flow $738M (SEC filings).
- Valuation: P/E 150.2x (avg 58.0x at the last 3 fiscal year-ends), EV/EBITDA 69.2x, net debt $3.31B.
- 3 of 80 tracked superinvestors hold BMRN (13F, Q2 2026): 0 new, 2 added, 1 reduced, 0 unchanged.
- Analysts: Buy (mean 2.07 on a 1–5 scale) (28 analysts), mean target USD 91.56 (range 60–122).
- Total return with dividends: 1Y +3.8% vs S&P 500 +14.9%; 5Y -23.2% vs S&P 500 +80.3%.
- Next earnings: 2026-10-26, EPS estimate USD -0.11, revenue estimate $1.02B.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $1.85B | $2.10B | $2.42B | $2.85B | $3.22B | $3.41B |
| Gross profit | $1.38B | $1.59B | $1.89B | $2.27B | $2.50B | — |
| Operating income | -$82.3M | $161M | $186M | $484M | $409M | $149M |
| Net income | -$64.1M | $142M | $168M | $427M | $349M | $73.0M |
| EPS (diluted) | -$0.35 | $0.75 | $0.87 | $2.21 | $1.80 | — |
| Free cash flow | $209M | $54.9M | $62.6M | $487M | $725M | $738M |
| Gross margin | 74.5% | 76.0% | 78.0% | 79.7% | 77.7% | — |
| Operating margin | -4.5% | 7.7% | 7.7% | 17.0% | 12.7% | 4.4% |
| Net margin | -3.5% | 6.8% | 6.9% | 15.0% | 10.8% | 2.1% |
| Revenue growth | -0.8% | +13.5% | +15.4% | +18.0% | +12.9% | — |
| Cash + short-term investments | $1.01B | $1.29B | $1.07B | $1.14B | $1.56B | — |
| Total debt | $1.08B | $1.08B | $593M | $595M | $597M | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 150.2x · P/S 3.2x · EV/EBITDA 69.2x · EV/Sales 4.2x · P/FCF 14.9x · P/B 1.7x · FCF yield 6.73% · Earnings yield 0.67% · Net debt $3.31B · EV $14.3B
P/E at fiscal year-ends: Dec 2025 33.6x, Dec 2024 30.3x, Dec 2023 110.2x.

## Superinvestors (SEC 13F-HR, Q2 2026)
3 of 80 tracked investors hold BMRN. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Viking Global | Viking Global Investors | 1.24% | $436M | Added +7.8% |
| Torray Funds |  | 0.60% | $4.4M | Reduced -0.6% |
| Dodge & Cox Funds | Dodge & Cox | 0.44% | $849M | Added +1.9% |

## Analysts
Consensus Buy (mean 2.07 on a 1–5 scale), 28 analysts; mean target USD 91.56 (low 60, high 122).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-21 | Morgan Stanley | Target lowered | Overweight | $124 → $122 |
| 2026-10-20 | JP Morgan | Target raised | Overweight | $86 → $87 |
| 2026-10-20 | Cantor Fitzgerald | Reiterated | Overweight | $86 |
| 2026-10-14 | Barclays | Target raised | Overweight | $111 → $114 |
| 2026-09-10 | HC Wainwright & Co. | Reiterated | Neutral | $60 |
| 2026-09-01 | Piper Sandler | Target raised | Overweight | $88 → $90 |
| 2026-08-31 | Jefferies | Target raised | Buy | $104 → $105 |
| 2026-08-31 | HC Wainwright & Co. | Target raised | Neutral | $59 → $60 |
| 2026-08-19 | BMO Capital | Initiated | Outperform | $98 |
| 2026-08-18 | HC Wainwright & Co. | Target lowered | Neutral | $60 → $59 |
| 2026-08-17 | Piper Sandler | Target raised | Overweight | $82 → $88 |
| 2026-08-17 | Barclays | Target raised | Overweight | $105 → $111 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +3.8% | -23.2% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +3.8% | -5.1% |
| Volatility (annualized) | 34.7% | 30.2% |
| Max drawdown | -22.6% (Aug 2026→Oct 2026) | -56.1% (Jan 2023→Nov 2025) |

## Peers (Biotechnology)
MDGL (Madrigal Pharmaceuticals, Inc.) USD 453.34 -1.01% · TECH (Bio-Techne Corp) USD 72.62 -0.03% · PCVX (Vaxcyte, Inc.) USD 62.85 -0.60% · TWST (Twist Bioscience Corporation) USD 135.47 -9.16% · KRYS (Krystal Biotech, Inc.) USD 320.13 -0.63% · KYMR (Kymera Therapeutics, Inc.) USD 110.85 -1.58%

## More
Full page: https://nexqual.com/BMRN · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Supply chain and relationships (SEC annual reports)


Other companies that name BMRN in their own reports (relationship from BMRN's side):

| Relationship | Company | Their filing | Sentence |
|---|---|---|---|
| partner | SPRUCE BIOSCIENCES, INC. (SPRB) | 10-K 2026-03-09 | "License Agreement with BioMarin Pharmaceutical, Inc." |
| partner | Camp4 Therapeutics Corp (CAMP) | 10-K 2026-03-05 | "In September 2024, we entered into a Collaboration and License Agreement (the "BioMarin Agreement") with BioMarin Pharmaceutical Inc. ("BioMarin"), pursuant to which we and BioMarin agreed to collabor…" |
| partner | Sarepta Therapeutics, Inc. (SRPT) | 10-K 2026-03-02 | "Under the terms of the License Agreement, we were required to pay the BioMarin Parties an up-front payment of $15.0 million" |

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $-0.11 | $1.49 | -107.5% | $1.02B | 13 |
| Next quarter (ends 2026-12-31) | $1.69 | $1.73 | -2.7% | $1.14B | 11 |
| Current fiscal year (ends 2026-12-31) | $3.51 | $4.93 | -29.0% | $3.92B | 14 |
| Next fiscal year (ends 2027-12-31) | $6.42 | $6.39 | +0.4% | $4.50B | 13 |